EDN3 and hemophilia B: The bioengineered design of ET3 can be compared in some regards to a strategy currently being pursued in AAV clinical gene therapy of hemophilia B where constructs encoding a naturally occurring human coagulation factor IX molecule termed factor IX-Padua that exhibits greater specific procoagulant activity than normal human fIX,27 and thus also increase vector potency.